204 related articles for article (PubMed ID: 12067686)
1. Culprit and victim -- DNA topoisomerase II.
Kellner U; Sehested M; Jensen PB; Gieseler F; Rudolph P
Lancet Oncol; 2002 Apr; 3(4):235-43. PubMed ID: 12067686
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase enzymes as drug targets.
Guichard SM; Danks MK
Curr Opin Oncol; 1999 Nov; 11(6):482-9. PubMed ID: 10550012
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II and the response to antileukemic therapy.
Kaufmann SH; Gore SD; Miller CB; Jones RJ; Zwelling LA; Schneider E; Burke PJ; Karp JE
Leuk Lymphoma; 1998 Apr; 29(3-4):217-37. PubMed ID: 9684921
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
Fortune JM; Osheroff N
Prog Nucleic Acid Res Mol Biol; 2000; 64():221-53. PubMed ID: 10697411
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
Tsunoda T
Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938
[No Abstract] [Full Text] [Related]
6. Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
Sinha BK
Drugs; 1995 Jan; 49(1):11-9. PubMed ID: 7705211
[TBL] [Abstract][Full Text] [Related]
7. From DNA damage to G2 arrest: the many roles of topoisomerase II.
Larsen AK; Escargueil AE; Skladanowski A
Prog Cell Cycle Res; 2003; 5():295-300. PubMed ID: 14593724
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerase II as a target of antineoplastic drug therapy.
Zwelling LA
Cancer Metastasis Rev; 1985; 4(4):263-76. PubMed ID: 3000574
[TBL] [Abstract][Full Text] [Related]
9. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).
Withoff S; De Jong S; De Vries EG; Mulder NH
Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy.
Giles GI; Sharma RP
Med Chem; 2005 Jul; 1(4):383-94. PubMed ID: 16789895
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of topoisomerase II-targeted antineoplastic drugs.
Osheroff N; Corbett AH; Robinson MJ
Adv Pharmacol; 1994; 29B():105-26. PubMed ID: 8996604
[No Abstract] [Full Text] [Related]
12. DNA topoisomerase II as a target for cancer chemotherapy.
Walker JV; Nitiss JL
Cancer Invest; 2002; 20(4):570-89. PubMed ID: 12094551
[No Abstract] [Full Text] [Related]
13. Topoisomerases II alpha and beta as therapy targets in breast cancer.
Isaacs RJ; Davies SL; Wells NJ; Harris AL
Anticancer Drugs; 1995 Apr; 6(2):195-211. PubMed ID: 7795268
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
[TBL] [Abstract][Full Text] [Related]
15. The function of DNA topoisomerases in UV-induced DNA excision repair: studies with specific inhibitors in permeabilized human fibroblasts.
Popanda O; Thielmann HW
Carcinogenesis; 1992 Dec; 13(12):2321-8. PubMed ID: 1335377
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerase II isozymes involved in anticancer drug action and resistance.
Fernandes DJ; Qiu J; Catapano CV
Adv Enzyme Regul; 1995; 35():265-81. PubMed ID: 7572348
[TBL] [Abstract][Full Text] [Related]
17. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
Etiévant C; Kruczynski A; Barret JM; Perrin D; van Hille B; Guminski Y; Hill BT
Cancer Chemother Pharmacol; 2000; 46(2):101-13. PubMed ID: 10972479
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II inhibitors.
Clapp JM; Hande KR
Cancer Chemother Biol Response Modif; 2002; 20():125-49. PubMed ID: 12703203
[No Abstract] [Full Text] [Related]
19. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Bridewell DJ; Finlay GJ; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
